2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study

BACKGROUND: Taniborbactam is an investigational β-lactamase inhibitor that restores cefepime (FEP) activity against FEP-, carbapenem-, and multidrug-resistant Enterobacterales and Pseudomonas aeruginosa producing serine- and metallo-β-lactamases. Cefepime-taniborbactam (FTB) was superior to meropene...

Descripción completa

Detalles Bibliográficos
Autores principales: Moeck, Greg, Gasink, Leanne, Dorr, Mary Beth, Chen, Hongzi, Woosley, Leah, Mendes, Rodrigo E, Wagenlehner, Florian, Henkel, Tim, McGovern, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678329/
http://dx.doi.org/10.1093/ofid/ofad500.2141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678329/
http://dx.doi.org/10.1093/ofid/ofad500.2141

Ejemplares similares